Cipla Ltd. — Regulatory Filings 2021

Mar 2, 2021

2[nd] March 2021

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087 Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release - Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

Dear Sir/Madam,

Please find enclosed press release dated 2[nd] March 2021 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully, For Cipla Limited

Digitally signed by RAJENDRA CHOPRA DN: c=IN, o=Personal, RAJENDR 2.5.4.20=4987ad48c3965cfde78c8ea69e6f40ac91535876f12ba1fa5ba45cc5cc8db 6cb, postalCode=122001, st=HARYANA, serialNumber=0be85c0408d0e3afd6636 A CHOPRA 69f5314248a72fdcdf34d01d48d472d7cf9262696f6, cn=RAJENDRA CHOPRA Date: 2021.03.02 08:44:00 +05'30'

Rajendra Chopra Company Secretary

Prepared by: Juzer Masta

Press Release

==> picture [90 x 50] intentionally omitted <==

Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

Mumbai, March 02, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that it’s subsidiary, Cipla Gulf FZ LCC (“Cipla Gulf’)is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of the biologic medicine brands, Aflibercept ( Eylea[®️] ), Ustekimumab ( Stelara ), Denosumab ( Prolia, Xgeva[®️] ) and Golimumab ( Simponi[®️] ). These are leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology (eg. Aflibercept is indicated for nAMD and other serious eye diseases).

The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks.These innovative products recorded US$700 Mn in aggregate 2020 sales in Australia.

Cipla Gulf had previously entered into a similar agreement with Alvotech in July 2019 for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.

Commenting on the partnership, Nishant Saxena, CEO, International Business (Europe & Emerging Markets), Cipla, said “Ensuring access to critical medicines is core to our purpose of ‘Caring for Life’ and this partnership is a step in that direction. We believe Alvotech’s products will enhance our biosimilars pipeline and allow us to establish a pantherapy presence in the specialties segment, improving our footprint in this strategic Australia market.”

Anil Okay, Alvotech’s Chief Commercial Officer said: “We are delighted to be taking this strategic step with Cipla. The combination of Alvotech’s development and manufacturing expertise and Cipla’s commercial capabilities will be central in expanding patient access in the region, to high-quality biosimilars.”

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT December’

==> picture [559 x 62] intentionally omitted <==

==> picture [90 x 50] intentionally omitted <==

20), 3rd largest in the pharma private market in South Africa (IQVIA MAT December’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigmchanging offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

About Alvotech:

Alvotech is a multinational biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets. We are specialists in biotechnology, seeking to be a global leader in the biosimilar space by delivering high quality, cost-competitive products and services to our partners and to patients worldwide. Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar products. Alvotech’s shareholder base includes, among others, Aztiq Pharma, led by founder and Chairman Mr. Robert Wessman, Cipla Gulf FZ from Australia and New Zeland, Shinhan from Korea, Baxter Healthcare SA, YAS Holdings, ATHOS (Strüngmann Family Office), CVC Capital Partners and Temasek from Singapore. Alvotech‘s initial pipeline contains several monoclonal-antibody and fusion-protein biosimilar candidates aimed at treating autoimmunity, oncology and inflammatory conditions to improve quality of life for patients around the world. For more information, please visit our website, www.alvotech.com or follow us on LinkedIn, Twitter and Facebook.

For queries, please contact :

Corporate Communications Investor Relations Heena Kanal Naveen Bansal E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com

==> picture [471 x 63] intentionally omitted <==

==> picture [559 x 62] intentionally omitted <==